359 related articles for article (PubMed ID: 31096737)
1. Clinical Targeted Next-Generation sequencing Panels for Detection of Somatic Variants in Gliomas.
Shin H; Sa JK; Bae JS; Koo H; Jin S; Cho HJ; Choi SW; Kyoung JM; Kim JY; Seo YJ; Joung JG; Kim NKD; Son DS; Chung J; Lee T; Kong DS; Choi JW; Seol HJ; Lee JI; Suh YL; Park WY; Nam DH
Cancer Res Treat; 2020 Jan; 52(1):41-50. PubMed ID: 31096737
[TBL] [Abstract][Full Text] [Related]
2. Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers.
Arcella A; Limanaqi F; Ferese R; Biagioni F; Oliva MA; Storto M; Fanelli M; Gambardella S; Fornai F
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31968687
[TBL] [Abstract][Full Text] [Related]
3. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
[TBL] [Abstract][Full Text] [Related]
4. Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels.
Ramarao-Milne P; Kondrashova O; Patch AM; Nones K; Koufariotis LT; Newell F; Addala V; Lakis V; Holmes O; Leonard C; Wood S; Xu Q; Mukhopadhyay P; Naeini MM; Steinfort D; Williamson JP; Bint M; Pahoff C; Nguyen PT; Twaddell S; Arnold D; Grainge C; Basirzadeh F; Fielding D; Dalley AJ; Chittoory H; Simpson PT; Aoude LG; Bonazzi VF; Patel K; Barbour AP; Fennell DA; Robinson BW; Creaney J; Hollway G; Pearson JV; Waddell N
ESMO Open; 2022 Aug; 7(4):100540. PubMed ID: 35849877
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Targeted Sequencing Panel for Hepatocellular Carcinoma Genomic Screening.
Paradiso V; Garofoli A; Tosti N; Lanzafame M; Perrina V; Quagliata L; Matter MS; Wieland S; Heim MH; Piscuoglio S; Ng CKY; Terracciano LM
J Mol Diagn; 2018 Nov; 20(6):836-848. PubMed ID: 30142445
[TBL] [Abstract][Full Text] [Related]
6. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors.
Nikiforova MN; Wald AI; Melan MA; Roy S; Zhong S; Hamilton RL; Lieberman FS; Drappatz J; Amankulor NM; Pollack IF; Nikiforov YE; Horbinski C
Neuro Oncol; 2016 Mar; 18(3):379-87. PubMed ID: 26681766
[TBL] [Abstract][Full Text] [Related]
7. Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas: Application of the World Health Organization's 2016 Revised Criteria for Central Nervous System Tumors.
Carter JH; McNulty SN; Cimino PJ; Cottrell CE; Heusel JW; Vigh-Conrad KA; Duncavage EJ
J Mol Diagn; 2017 Mar; 19(2):328-337. PubMed ID: 28042970
[TBL] [Abstract][Full Text] [Related]
8. Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer.
Kaur P; Porras TB; Ring A; Carpten JD; Lang JE
Sci Rep; 2019 Feb; 9(1):1482. PubMed ID: 30728399
[TBL] [Abstract][Full Text] [Related]
9. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases.
Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH
J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203
[TBL] [Abstract][Full Text] [Related]
10. Exome sequencing covers >98% of mutations identified on targeted next generation sequencing panels.
LaDuca H; Farwell KD; Vuong H; Lu HM; Mu W; Shahmirzadi L; Tang S; Chen J; Bhide S; Chao EC
PLoS One; 2017; 12(2):e0170843. PubMed ID: 28152038
[TBL] [Abstract][Full Text] [Related]
11. Molecular profile and clinical features of patients with gliomas using a broad targeted next generation-sequencing panel.
Romanidou O; Apostolou P; Kouvelakis K; Tsangaras K; Eliades A; Achilleos A; Loizides C; Lemesios C; Ioannides M; Kypri E; Koumbaris G; Papadopoulou K; Papathanasiou A; Rigakos G; Xanthakis I; Fostira F; Kotoula V; Fountzilas G; Patsalis PC
Oncol Lett; 2023 Jan; 25(1):38. PubMed ID: 36589665
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics.
Misyura M; Zhang T; Sukhai MA; Thomas M; Garg S; Kamel-Reid S; Stockley TL
J Mol Diagn; 2016 Nov; 18(6):842-850. PubMed ID: 27770852
[TBL] [Abstract][Full Text] [Related]
13. Next generation sequencing using phenotype-based panels for genetic testing in inherited retinal diseases.
Shah M; Shanks M; Packham E; Williams J; Haysmoore J; MacLaren RE; Németh AH; Clouston P; Downes SM
Ophthalmic Genet; 2020 Aug; 41(4):331-337. PubMed ID: 32543920
[TBL] [Abstract][Full Text] [Related]
14. Integrated next-generation sequencing analysis of whole exome and 409 cancer-related genes.
Shimoda Y; Nagashima T; Urakami K; Tanabe T; Saito J; Naruoka A; Serizawa M; Mochizuki T; Ohshima K; Ohnami S; Ohnami S; Kusuhara M; Yamaguchi K
Biomed Res; 2016; 37(6):367-379. PubMed ID: 28003584
[TBL] [Abstract][Full Text] [Related]
15. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
[TBL] [Abstract][Full Text] [Related]
16. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
[TBL] [Abstract][Full Text] [Related]
17. A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications.
Tirrò E; Massimino M; Broggi G; Romano C; Minasi S; Gianno F; Antonelli M; Motta G; Certo F; Altieri R; Manzella L; Caltabiano R; Barbagallo GMV; Buttarelli FR; Magro G; Giangaspero F; Vigneri P
Front Oncol; 2022; 12():861078. PubMed ID: 35372034
[TBL] [Abstract][Full Text] [Related]
18. The combination of whole-exome sequencing and copy number variation sequencing enables the diagnosis of rare neurological disorders.
Jiao Q; Sun H; Zhang H; Wang R; Li S; Sun D; Yang XA; Jin Y
Clin Genet; 2019 Aug; 96(2):140-150. PubMed ID: 30945278
[TBL] [Abstract][Full Text] [Related]
19. Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes.
Soukupova J; Zemankova P; Lhotova K; Janatova M; Borecka M; Stolarova L; Lhota F; Foretova L; Machackova E; Stranecky V; Tavandzis S; Kleiblova P; Vocka M; Hartmannova H; Hodanova K; Kmoch S; Kleibl Z
PLoS One; 2018; 13(4):e0195761. PubMed ID: 29649263
[TBL] [Abstract][Full Text] [Related]
20. High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.
Su D; Zhang D; Chen K; Lu J; Wu J; Cao X; Ying L; Jin Q; Ye Y; Xie Z; Xiong L; Mao W; Li F
J Exp Clin Cancer Res; 2017 Sep; 36(1):121. PubMed ID: 28882180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
